Startup profile · funding coverage
Basecamp Research funding, valuation and investors
AI-native drug discovery company using biological data gathered from global biodiversity.
Keep track of Basecamp Research
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series C
$140M · September 23, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$140M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
growth · London, United Kingdom
Overview
Basecamp Research develops biological foundation models and AI-designed therapeutic programs using proprietary datasets built from global biodiversity.
Why Basecamp Research is interesting
Its Series C moves a data-platform thesis toward preclinical cell-therapy programs, where biological validation and clinical execution become the key risks.
Key facts
- Latest financing: $140M (Series C)
Funding history (newest first)
Series C
2026-09-23 $140MMarket / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover Basecamp Research's financing or category context.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.